enow.com Web Search

  1. Ad

    related to: herceptin fda approval history

Search results

  1. Results from the WOW.Com Content Network
  2. Trastuzumab - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab

    Herceptin was Fast-tracked by the FDA and gained approval in September 1998. [34] Biocon Ltd and its partner Mylan obtained regulatory approval to sell a biosimilar in 2014, but Roche contested the legality of the approval; that litigation ended in 2016, and Biocon and Mylan each introduced their own branded biosimilars. [78]

  3. Trastuzumab deruxtecan - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_deruxtecan

    Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease. [16] The FDA approved trastuzumab deruxtecan for the treatment of HER2-low breast cancer based on DESTINY-Breast04, a randomized, multicenter, open label clinical trial that enrolled 557 adult participants with unresectable ...

  4. Trastuzumab emtansine - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_emtansine

    The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine in February 2013, and granted the application for Kadcyla to Genentech. [18] The FDA granted the application for trastuzumab emtansine priority review and breakthrough therapy designations. [24] In 2013, trastuzumab emtansine was approved in the UK, [4] and the EU. [6]

  5. Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

    www.aol.com/news/amgen-allergan-fda-nod...

    FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

  6. FDA Setback for Roche and Immunogen Breast Cancer Treatment - AOL

    www.aol.com/news/2010-08-27-fda-setback-roche...

    The world's biggest cancer-drugs maker Roche (RHHBY) was dealt another setback Friday. The U.S. Food and Drug Administration rejected Roche's request for accelerated approval of its trastuzumab ...

  7. Timeline of cancer treatment development - Wikipedia

    en.wikipedia.org/wiki/Timeline_of_cancer...

    2004 – bevacizumab, the first approved drug to inhibit blood vessel formation by tumours, is licensed [4] 2005 – US FDA approves taxol for chemotherapy of breast, pancreatic, and non-small cell lung cancers [43] 2006 – US FDA approves herceptin [10] 2007 – US FDA approves sorafenib [10]

  8. FDA Advisory Committee Recommends Accelerated Approval of ...

    www.aol.com/news/2013-09-12-fda-advisory...

    FDA Advisory Committee Recommends Accelerated Approval of Genentech's Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer The FDA Will Make a Final Decision by October 31 The ...

  9. Trastuzumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab/hyaluronidase

    Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast ...

  1. Ad

    related to: herceptin fda approval history